Correspondence: Andre Ambrus, MLIS, American Academy of Ophthalmology, Quality and Data Science, P.O. Box 7424, San Francisco, CA 94120-7424. E-mail: [email protected] .

Disclosure(s): All authors have completed and submitted the ICMJE disclosures form.

The author(s) have made the following disclosure(s): E.J.W., V.K.A., S.K.F., and J.P.T.: Consultant fees – Horizon Therapeutics.

E.J.W.: Consultant fees – Valeant Pharmaceuticals; Equity – Praxis Biotechnology.

V.K.A.: Equity stake – ViSo Therapeutics Inc.

Funded without commercial support by the American Academy of Ophthalmology .

HUMAN SUBJECTS: No human subjects were included in this study. The requirement for informed consent was waived because of the retrospective nature of the study. All research adhered to the tenets of the Declaration of Helsinki.

No animal subjects were included in this study.

Author Contributions:

Conception and design: Tao, Aakalu, Freitag, Sobel, Foster, Wladis, McCulley, Yen

Analysis and interpretation: Tao, Aakalu, Freitag, Sobel, Foster, Wladis, McCulley, Yen

Data collection: Tao, Aakalu, Freitag, Sobel, Foster, Wladis, McCulley, Yen

Obtained funding: N/A

Overall responsibility: Tao, Aakalu, Freitag, Sobel, Foster, Wladis, McCulley, Yen